08:00 , Dec 13, 2010 |  BC Week In Review  |  Company News

Stellar Biotechnologies, Bayer deal

Stellar received an exclusive, worldwide license to technology developed under a 2009 deal with Bayer's Bayer Innovation GmbH subsidiary to develop the pharma's personalized vaccine from tobacco plants. Bayer has rights to use the technology...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Company News

Stellar Biotechnologies, Bayer deal

Stellar received the second and final undisclosed milestone payment from Bayer's Bayer Innovation GmbH subsidiary under a 2009 deal to develop the pharma's personalized vaccine from tobacco plants. Under the deal, Stellar is providing keyhole...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Company News

AmVac, Bayer deal

AmVac and Bayer’s Bayer Innovation GmbH subsidiary partnered to research and develop an influenza vaccine using antigens that Bayer’s Icon Genetics GmbH subsidiary will produce in tobacco plants. The vaccine will use AmVac’s MALP-2, a...
07:00 , Jun 4, 2004 |  BC Extra  |  Company News

Munich Biotech files for insolvency

Cancer play Munich Biotech (Neuried, Germany) said it filed for insolvency last week. The company's MBT-0206 intravenous paclitaxel is in Phase II testing to treat metastatic breast cancer and metastatic pancreatic cancer. The company's MBT-0312...
08:00 , Jan 14, 2002 |  BioCentury  |  Finance

Ebb & Flow

'The great tragedy of science - the slaying of a beautiful hypothesis by an ugly fact.' - Biologist Thomas Henry Huxley It was hard to ignore the level of swagger and hubris among company executives...
08:00 , Nov 8, 1999 |  BioCentury  |  Finance

NASDAQ targets Europe

NASDAQ targets Europe The turf battle to capture the hearts and minds of European capital stepped up a gear last Friday when the National Association of Securities Dealers announced plans to create a pan-European platform...
07:00 , Apr 6, 1998 |  BC Week In Review  |  Company News

Symyx, Bayer deal

The partners will use Symyx's combinatorial chemistry to discover and develop new catalysts, polymers and electronic materials. Symyx could receive $42.1 million in research funding from Bayer, $8.1 of which is guaranteed through February 2000....
08:00 , Dec 8, 1997 |  BioCentury  |  Finance

Disgruntled

The Biotechnology Value Fund was to announce today that it is opposed to the proposed merger between Arris and Sequana . The fund holds a 5 percent stake in ARRS, according to fund manager Mark...
08:00 , Dec 8, 1997 |  BioCentury  |  Strategy

Wanted: Passionate entreprenuers

OXFORD - Anyone who has looked at the development of the global biotech industry cannot be unimpressed by the efforts now being made by some continental European governments, particularly in Germany, to stimulate the development...